New York, Feb 14, 2026, 16:18 ET — The market is shut for the day.
- Shares of Vertex jumped 5.7%, landing at $491.47 on Friday, following an upgrade from Oppenheimer.
- Vertex’s 2026 forecast shifted attention to its pipeline outside cystic fibrosis—kidney, pain, and gene-editing treatments now in the spotlight.
- U.S. markets are closed Monday for Presidents Day. Investors are eyeing what happens next once trading picks back up.
Shares of Vertex Pharmaceuticals Inc jumped 5.7% to close at $491.47 on Friday, pushing the Boston biotech into focus ahead of the holiday-shortened week. Oppenheimer’s Jay Olson gave the stock an upgrade to “Outperform” and set a $540 target. StockAnalysis
Here’s what’s moving: Vertex, in its Thursday SEC filing, laid out a 2026 revenue target between $12.95 billion and $13.1 billion, projecting at least $500 million from non-cystic fibrosis products. CEO Reshma Kewalramani pointed to three main priorities for 2026: broadening the roll-out of gene-editing treatment Casgevy, ramping up non-opioid pain drug Journavx, and preparing a U.S. submission for kidney therapy povetacicept.
Vertex’s outlook midpoint matched Wall Street’s targets, and the latest quarter landed pretty much where analysts figured. That’s a no-surprises profile, but it can still shift a stock if investors want confirmation the cystic-fibrosis heavyweight is finding ways to expand. Adjusted fourth-quarter earnings clocked in at $5.03 per share, just shy of the $5.07 consensus. Revenue climbed roughly 10%, coming in at $3.19 billion, nearly identical to the $3.18 billion analysts had penciled in, according to Reuters.
Friday brought a muted session for the broader market. The S&P 500 eked out a slight gain, while Treasury yields dipped following softer U.S. inflation numbers. That combination set the stage for investors to zero in on individual stocks, with one investor describing the mood as positioning for a “long holiday weekend.” Reuters
The U.S. stock markets shut down for Presidents Day on Monday, Feb. 16, trimming the trading week and giving investors less time to adjust ahead of Tuesday’s open.
Vertex investors are staring down some blunt questions: will the cystic fibrosis business keep expanding as new product launches come into play, and does the kidney pipeline justify a higher multiple—one the stock hasn’t reliably maintained?
Oppenheimer’s note put the spotlight on Vertex’s renal pipeline, which is now drawing increased market focus. Drug development remains a game of binary outcomes; a single data release can flip the story fast, and those initial commercial ramps that look strong in presentations sometimes tell a different story once the claims data rolls in.
Still, plenty could trip this up. Shifting prescribing habits for a non-opioid pain drug isn’t easy, gene-editing treatments bring their own delivery hurdles, and kidney-disease data can slap down optimism in a hurry if there’s any sign of trouble with efficacy or safety.
The next major event for investors: data on povetacicept in IgA nephropathy, a chronic kidney disorder. BioSpace noted that Kewalramani told investors the independent board overseeing the pivotal trial “have not asked us to change anything.” BMO Capital Markets flagged the soon-to-come proteinuria data as “critical,” with rivals including Otsuka’s Voyxact and Vera Therapeutics’ atacicept program pressing in. biospace.com
